Day One

7:20 am Coffee & Registration

8:20 am Chair’s Opening Remarks

Harnessing the Power of PDXs to Accelerate Drug Development

8:30 am Optimising Orthotopic Bladder Cancer Models for Preclinical Testing of Intravesical Therapies

  • Lucas Trucco Principal Scientist, Oncology, Johnson & Johnson Innovative Medicine

Synopsis

  • Establishing orthotopic bladder xenograft models that resemble local urothelial carcinomas using a minimally invasive method
  • Monitoring tumour burden with bioluminescence imaging and histologic analysis for efficacy evaluation
  • Validating the approach by demonstrating a dose-dependent response upon intravesical treatment

9:00 am Preclinical Development of DuoBody®-CD3xB7H4 – a Novel CD3 Bispecific Antibody for the Treatment of Solid Cancers

  • Madelon Paauwe Senior Scientist – Preclinical In Vivo Pharmacology, Genmab

Synopsis

  • Exploring the preclinical use of CD3xB7H4 in humanised mice
  • Analysing bispecific antibody development to treat cancers

9:30 am Investigating PDX Models to Study Resistance Mechanism of Neuroendocrine Prostate Cancers

Synopsis

  • Showcasing data gathered from testing molecules of different PDX models
  • Elucidating the mechanisms of resistance of prostate cancer to therapeutics

10:00 am Speed Networking

Synopsis

Join our speed networking session tailored for preclinical and translational experts to connect with industry peers & facilitating rapid yet meaningful exchanges of insights and expertise

10:30 am Morning Break & Networking

11:00 am Presented by Certis Oncology

Utilising Mouse Models to Investigate Tumour Resistance, Microenvironment, & Immunotherapy Anti-Tumour Mechanisms

11:30 am Utilising Humanised Mouse Models to Enhance Cancer Vaccine Research

  • Joel Plumas Co- Founder & Chief Scientific Officer, PDC*line Pharma

Synopsis

  • Evaluating the therapeutic effects of human PDC cell-based cancer vaccines in human-tumour bearing mouse models
  • Exploring tumour resistance and evolution in humanised mouse models
  • Characterising the human tumour microenvironment
  • Demonstrating in vivo therapeutic efficacy

12:00 pm Presented by Lide

12:30 pm Lunch & Networking

1:30 pm Presented by GenOway

2:00 pm Investigating Safety & Efficacy of IOMX-0675 a Cross-Specific Antibody Unleashing Tumor Microenvironment Repolarisation & Activation by Targeting LILRB1/2 in Innovative In Vitro, Ex Vivo & Humanised In Vivo Cancer Models

  • Stefan Bissinger Head of Preclinical Pharmacology & Biomarker Development, iOmx Therapeutics

Synopsis

  • Selection and characterisation of the best-in class candidate IOMX-0675 using in vitro primary immune cells assays and ex vivo whole blood systems
  • Translating myeloid – T cell biology into pharmacodynamic activity in advanced myeloid engrafted humanised mouse models

2:30 pm Presented by GemPharmatech

3:00 pm Afternoon Break & Networking

3:30 pm Utilising Novel GEMMs to Study Anti-Tumour Mechanisms of Prokarium’s ZH9 Immunotherapy Platform

Synopsis

  • Introducing Prokarium’s product and goals of the platform
  • Evaluating the right models for more advanced diseases
  • Exploring the use of GEMMs to study bladder cancer 

4:00 pm Assessing Techniques to Improve the TME for Therapeutic Discovery & Development

Synopsis

  • Highlighting the importance of designing tumour models that accurately represent the immune component to effectively evaluate immuno-oncology therapies
  • Uncovering methods for TME remodelling to promote immune activation
  • Implementing tumour models including CDX/PDX mice and 3D tissue model systems to assess combination therapies of cancer vaccines with checkpoint inhibitors

4:30 pm OMX-0407 a Spectrum Selective Kinase Inhibitor Shows Preclinical & Clinical Efficacy in Angiosarcoma

Synopsis

  • Demonstrating striking anti-tumour efficacy in a rare indication PDX of an Angiosarcoma with a comprehensive mode of action analysis
  • Translating research into the first clinical findings with one responder patient in a Ph1a study

5:00 pm Closing Remarks

5:10 pm Tumour Models Drinks Reception & Poster Session

Synopsis

Join our dedicated drinks reception and poster session to further connect and network with like-minded experts whilst obtaining competitive insights from innovative work submitted by your peers!

6:10 pm End of Day One